These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Alloimmunization as a problem for platelet transfusion. Bonacossa IA Transfus Med Rev; 1990 Apr; 4(2):144-8. PubMed ID: 2134622 [No Abstract] [Full Text] [Related]
5. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation. Snyder EL Yale J Biol Med; 1990; 63(5):419-27. PubMed ID: 2293501 [TBL] [Abstract][Full Text] [Related]
6. Prevention and circumvention of refractoriness to platelet transfusions: interface between preparative and therapeutic apheresis. Beris P; Dornier C Curr Stud Hematol Blood Transfus; 1990; (57):267-76. PubMed ID: 2272206 [No Abstract] [Full Text] [Related]
7. Alloantibodies and platelet destruction. Klein CA; Blajchman MA Semin Thromb Hemost; 1982 Apr; 8(2):105-15. PubMed ID: 7043738 [No Abstract] [Full Text] [Related]
8. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Fisher M; Chapman JR; Ting A; Morris PJ Vox Sang; 1985; 49(5):331-5. PubMed ID: 3909636 [TBL] [Abstract][Full Text] [Related]
10. [Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation]. Delbos F; Cesbron A Transfus Clin Biol; 2017 Sep; 24(3):131-137. PubMed ID: 28757117 [TBL] [Abstract][Full Text] [Related]
11. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness]. Basire A; Picard C Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Vamvakas EC Transfus Med Rev; 1998 Oct; 12(4):258-70. PubMed ID: 9798269 [No Abstract] [Full Text] [Related]
13. [The effect of HLA alloimmunization and other factors on the effectiveness of thrombocyte concentrates]. Pittrová H; Koza V; Cepelák V; Bufková D Cas Lek Cesk; 1990 Jun; 129(24):751-3. PubMed ID: 2393882 [TBL] [Abstract][Full Text] [Related]
14. Use of HLA- and HPA--matched platelets in alloimmunized patients. Kekomäki R Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468 [TBL] [Abstract][Full Text] [Related]
15. Serological studies in patients on platelet- and granulocyte-substitution therapy. Pegels JG; Bruynes EC; Engelriet CP; von dem Borne AE Br J Haematol; 1982 Sep; 52(1):59-68. PubMed ID: 7115629 [TBL] [Abstract][Full Text] [Related]
16. [HLA compatibility and transfusion of a platelet concentrate--a necessary prerequisite for the successful transfusion of platelet concentrates in patients with HLA antibodies]. Májský A; Korínková P; Vítek A Cas Lek Cesk; 1986 Mar; 125(12):363-5. PubMed ID: 3955595 [No Abstract] [Full Text] [Related]
17. [Platelet transfusion refractoriness and effective management of platelet alloimmunization]. Amemiya Y Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306 [TBL] [Abstract][Full Text] [Related]
18. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection. Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444 [TBL] [Abstract][Full Text] [Related]